Login / Signup

Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist.

Davide SimonatoRobin J BorchertMarc-Antoine LabeyrieMaurizio FuschiLucie ThibaultHans HenkesDavid FiorellaBenjamin Yq TanLeonard Leong-Litt YeoHegoda Ld MakalandaKen WongPervinder Bhogal
Published in: Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences (2021)
Antiplatelet therapies are commonly used in neurointerventional procedures. However, specific guidelines for their use in these settings is lacking and it can often be difficult to balance the potential risks and benefits of these medications. Considering the continued growth and adoption of neurointerventional procedures, it is crucial to understand the properties of these agents in order to use them safely. Large-scale clinical trials are still needed to clarify many of these aspects for this emerging field. However, the existing literature already provides insight into which antiplatelet drugs are of benefit to the neurointerventionalist as well as their associated risks of ischemic and hemorrhagic complications. Hence, this review focuses on the applications of GPIIb/IIIA inhibitors to neurointerventional procedures.
Keyphrases
  • human health
  • clinical trial
  • systematic review
  • risk assessment
  • risk factors
  • clinical practice
  • climate change
  • open label
  • double blind
  • phase iii